Monthly Archives: February 2015

Novo Nordisk (NVO-NYSE, $47.12) Successfully Demonstrates Oral GLP1 Efficacy.

Novo Nordisk, a long held position within the model portfolio, today announced phase 2 test results on its new oral diabetes medication. http://news.investors.com/022015-740166-novo-nordisk-lauds-phase-two-trial-for-diabetes-drug.htm?ven=yahoocp&src=aurlled&ven=yahoo There are potential breakthrough implications that one can glean from this result. Until now, the newest and

Posted in Open Blog

American Express (AXP-NYSE,$78.04) losing business to Mastercard (MA-NYSE, $87.14) and Visa (V-NYSE, $269.63) allies.

In recent weeks, American Express has announced that the Costco processing and co-brand partnership will end in 2016. The implication is that either MasterCard (MA-NYSE, $87.14) via its issuing partners, or Visa, through its issuing partners, will assume the contract

Posted in Open Blog